This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Misunderstood ATOs Are Costing Agencies Time, Money
Institutional confusion about ATOs is creating avoidable delays, while modern DevSecOps approaches offer a faster path to software delivery.
9m watch -
AI Powers Smithsonian’s Digital Transformation for America250
The Smithsonian is applying AI to research, digital collections and visitor experiences as it prepares for America250.
12m listen -
Inside DOE's Effort to Use AI for Nuclear Waste Cleanup
Eric Pierce explains how Savannah River National Laboratory is using AI to modernize environmental monitoring and waste cleanup.
12m listen -
Wellness Tips for Cyber Leaders at Home
Avni Desai is a dedicated professional at CGI, where she brings a thoughtful blend of leadership, strategic insight and a people‑centered approach to her work.
46m watch